Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.60 |
| ▸ | ITGAV | P06756 | 6/20 | 0.60 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.60 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.60 |
| ▸ | MC4R | P32245 | 10/20 | 0.56 |
| ▸ | MC5R | P33032 | 10/20 | 0.56 |
| ▸ | MC3R | P41968 | 10/20 | 0.56 |
| ▸ | MC1R | Q01726 | 10/20 | 0.56 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397366 | 1.00 | ITGB3 (0.60) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL12462935 | 0.94 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL24253307 | 0.94 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL19605457 | 0.94 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL24285406 | 0.92 | ITGB3 (0.60) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL10259650 | 0.92 | MC4R (0.62) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL24253223 | 0.92 | ITGB3 (0.58) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL24253222 | 0.92 | ITGB3 (0.58) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL12146076 | 0.91 | ITGB3 (0.50) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL21766911 | 0.91 | ITGB3 (0.58) | ITGB3ITGAVITGB1ITGA5MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046735-A1 | PLASMA MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046735-A1 | PLASMA MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2008006097-A2 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES LLC (US) | 2008-01-10 | — | — | WO | disclosed |
| US-7179446-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | ITGAL, ITGA1, ITGA5 | ITGB3 12/4885ITGAV 24/4885ITGB1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.